Phio Pharmaceuticals
PHIO
12 hedge funds and large institutions have $551K invested in Phio Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 6 closing their positions.
0% more ownership
Funds ownership: 0.05% → 0.05% (+0%)
12% less capital invested
Capital invested by funds: $626K → $551K (-$75K)
14% less funds holding
Funds holding: 14 → 12 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$168K |
| 2 |
Two Sigma Investments
New York
|
+$24.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.14K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$376 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$94 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$41K |
| 2 |
BlackRock
New York
|
-$30.4K |
| 3 |
VF
Virtu Financial
New York
|
-$23.8K |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$13.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$11.3K |
PHIO Hedge Fund Activity: Q2 2022 in Review
12 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2022, worth a combined $551K — down 12% from $626K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PHIO and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $168K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $41K sold.
- 12 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2022, down from 14 in Q1 2022.
- Funds reported $551K of Phio Pharmaceuticals stock for Q2 2022, down 12% quarter-over-quarter.
- 4 funds opened new Phio Pharmaceuticals positions in Q2 2022 and 6 closed out, a net change of -2 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $168K added.
- The largest Phio Pharmaceuticals seller in Q2 2022 was Two Sigma Advisers, an estimated $41K sold.
Based on aggregated 13F filings for Q2 2022.